[Click e-Stock] "Orion Holdings, Reviewing Bio Investment Performance"

On October 21, IBK Investment & Securities raised its target price for Orion Holdings from 21,000 won to 28,000 won, stating that the investment in its bio division, now in its fifth year, is gradually yielding results and is expected to achieve notable outcomes alongside its food division in the future. The firm maintained its 'Buy' recommendation.

Previously, in November 2022, Orion Holdings established Orion Biologics to pursue the dental disease treatment business, focusing on the development and commercialization of both consumer products and specialized pharmaceuticals for dental diseases such as tooth sensitivity, cavities, and periodontal disease.

Nam Seonghyeon, a researcher at IBK Investment & Securities, explained, "So far, the company has completed phase 2b clinical trials in Korea for its tooth sensitivity treatment and is currently conducting phase 2b trials in the United States. In the short term, it plans to launch a functional toothpaste in Southeast Asia early next year, thereby accelerating the expansion of its consumer business."

In China, the company is also pursuing a colorectal cancer in vitro diagnostic kit business by transferring technology from Genomictree. It has applied for product approval in partnership with Shandong Lukang Pharmaceutical, a state-owned Chinese pharmaceutical company.

Nam further commented, "The tuberculosis vaccine division is also expected to achieve significant results in China over the medium to long term. This market is showing active progress, driven by Chinese government policies aimed at reducing the incidence of tuberculosis." Recently, the company received approximately 3 billion won in government funding and is collaborating with the National Center for Tuberculosis in China. Given that Quratis has already completed phase 2a trials in Korea and conducted two clinical trials in the United States and one in South Africa, the likelihood of passing clinical trials in China is considered high.

This content was produced with the assistance of AI translation services.